The Munich-based digital health company Ebenbuild receives 2.3 million euros from the European Commission's EIC Accelerator Program to further develop its digital lung twin platform. In addition, the EIC fund is providing up to 10 million euros for future equity financing rounds. Ebenbuild intends to use the capital to bring its Twinhale software to market maturity.
Ebenbuild, a Munich-based start-up specializing in digital twins of the lung, was selected by the EIC Accelerator Program for its pioneering technology platform. The total funding comprises 2.3 million euros in the form of a non-dilutive grant and up to 10 million euros from the EIC Fund for future investment rounds.
The focus of the funding is Twinhale - the first scalable simulation software for patient-specific prediction of drug distribution in the lungs. The technology enables pharmaceutical and medical technology companies to precisely simulate inhalation therapies digitally. The aim is to make clinical trials more efficient, reduce development risks and accelerate the market launch of innovative therapies.
The platform has already been tested in pilot studies with PARI Pharma and Pieris Pharmaceuticals. In a validation study, Twinhale achieved a particularly accurate prediction of local drug deposition in the lungs, which represents a decisive advantage over established in vivo and in vitro models.
Ebenbuild is financed by High-Tech Gründerfonds (HTGF), Bayern Kapital and business angels, among others. The company is positioning itself in a rapidly growing market for in silico trials (over EUR 5 billion) and is also aiming to enter the clinical decision support systems (CDSS) and personalized medicine segments in the medium term - together with an estimated market volume of over EUR 300 billion by 2030.
“Our vision is to become the leading health intelligence platform for respiratory diseases,” said Dr. Kei Müller, CEO and Co-founder of the Company. “Twinhale is just the beginning. The very same core platform will power future regulated products for mechanical ventilation optimization and chronic respiratory disease management.”
In the long term, Ebenbuild is pursuing a product roadmap that ranges from preclinical simulations to clinical decision-making aids. The next development goal is software to optimize mechanical ventilation for patients with lung complications - a market with a volume of around 10 billion euros and high medical demand.